May. 5 at 11:16 AM
$IRMD iRadimed reports Q1 adjusted EPS 42c vs 36c last year
Reports Q1 revenue
$19.5M vs
$17.6M last year. "We are excited to begin 2025 with our fifteenth consecutive quarter of record revenue, achieving
$19.5 million in the first quarter, an 11% increase year-over-year. This impressive top-line performance, coupled with a 16% rise year-over-year in diluted EPS, highlights the sustained demand for our innovative products and our team's dedication to operational excellence.
We are also pleased to maintain our quarterly cash dividend at
$0.17 per share, underscoring our commitment to delivering value to our shareholders. With our new manufacturing facility on track for completion in July 2025, we are well-positioned to support our planned growth and build upon the momentum of our strong first quarter performance," said Roger Susi, President and Chief Executive Officer of Iradimed Corporation.
